Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 57 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. The company also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.

Industry: Pharmaceutical Preparations Peers: 4D Molecular Therapeutics Inc Whitehawk Therapeutics Inc Vaxart Inc Outlook Therapeutics Inc Poseida Therapeutics, Inc. Cartesian Therapeutics Inc Summit Therapeutics Inc